Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism

Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy

(2016) Yin Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages

(2016) Yunlong Yang et al.   Nature Communications

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

(2015) Lieke H J Simkens et al.   LANCET

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial

(2015) Susanna Hegewisch-Becker et al.   LANCET ONCOLOGY

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

(2015) Josep Tabernero et al.   LANCET ONCOLOGY

VEGF-B promotes cancer metastasis through a VEGF-A–independent mechanism and serves as a marker of poor prognosis for cancer patients

(2015) Xiaojuan Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

VEGF-B-Neuropilin-1 signaling is spatiotemporally indispensable for vascular and neuronal development in zebrafish

(2015) Lasse D. Jensen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PlGF-induced VEGFR1-dependent vascular remodeling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors

(2015) H. Iwamoto et al.   Science Advances

VEGF-VEGFR Signals in Health and Disease

(2014) Masabumi Shibuya   Biomolecules & Therapeutics

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

(2014) Volker Heinemann et al.   LANCET ONCOLOGY

VEGF-targeted cancer therapeutics—paradoxical effects in endocrine organs

(2014) Yihai Cao   Nature Reviews Endocrinology

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

(2014) Fotios Loupakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of age-related insulin sensitivity by VEGF-dependent vascular plasticity in adipose tissues

(2014) J. Honek et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling

(2014) Hong Ji et al.   Nature Communications

VEGFR2-Mediated Vascular Dilation as a Mechanism of VEGF-Induced Anemia and Bone Marrow Cell Mobilization

(2014) Sharon Lim et al.   Cell Reports

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

(2013) Ian F Tannock et al.   LANCET ONCOLOGY

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

(2013) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth

(2013) Xiaojuan Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues

(2013) Y. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again?

(2011) Ruslan Hlushchuk et al.   INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY

Podocin-Green Fluorescence Protein Allows Visualization and Functional Analysis of Podocytes

(2011) B. He et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells

(2011) Yuan Xue et al.   NATURE MEDICINE

Changing End Points in Breast-Cancer Drug Approval — The Avastin Story

(2011) Ralph B. D'Agostino   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

(2010) Richard M. Zuniga et al.   JOURNAL OF NEURO-ONCOLOGY

A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models

(2010) Yanlan Yu et al.   PLoS One

Optimizing the Delivery of Cancer Drugs That Block Angiogenesis

(2010) Y. Cao et al.   Science Translational Medicine

Vascular Endothelial Growth Factor

(2009) Napoleone Ferrara   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment

(2009) Yongping Crawford et al.   CANCER CELL

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance

(2009) Yihai Cao et al.   SEMINARS IN CANCER BIOLOGY

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE